Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
02 December, 2020 00:33 IST
Aurobindo Pharma receives EIR for Hyderabad unit
Source: IRIS | 19 Feb, 2020, 05.39PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Aurobindo Pharma, a mid-size pharmaceutical company, notified the stock exchanges that it had received an establishment inspection report (EIR) from the US drug regulator (USFDA) for Hyderabad unit.

It said ''the company has received EIR with voluntary action initiated (VAI) status from the United States Food and Drug Administration (USFDA).''

In November, USFDA inspected Unit IV, a general injectable formulation manufacturing facility at Pashamylaram in Hyderabad and had issued 'Form 483' with 14 observations.

Shares of the company gained Rs 102.05, or 20.4%, to settle at Rs 602.25. The total volume of shares traded was 897,415 at the BSE (Wednesday).

 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
TVS Motor Company sales grows 21% in November 2020 - 01-Dec-2020 19:01
Kilpest India net profit jumps over two-fold to Rs 11.31 mn in July-September - 01-Dec-2020 17:10
Kilpest India sells 6,10,100 COVID19 RT-PCR tests in November - 01-Dec-2020 16:36
Mahindra Auto Sector sells 42,731 vehicles in November - 01-Dec-2020 14:20
IDBI Bank redeems 4.25% Senior Notes worth USD 350 mn - 01-Dec-2020 14:00
Chartered Logistics swings to net loss of Rs 4.20 mn in Q2 - 01-Dec-2020 13:33
Chartered Logistics transfers equity shares to IEPF - 01-Dec-2020 13:10
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer